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Changes of the mucosal n3 and n6 fatty acid
status occur early in the colorectal
adenoma-carcinoma sequence
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Abstract
Despite data favouring a role ofdietary fat
in colonic carcinogenesis, no study has
focused on tissue n3 and n6 fatty acid (FA)
status in human colon adenoma-carci-
noma sequence. Thus, FA profile was
measured in plasma phospholipids of
patients with colorectal cancer (n=22),
sporadic adenoma (n=27), and normal
colon (n= 12) (control group). Addi-
tionally, mucosal FAs were assessed in
both diseased and normal mucosa of
cancer (n= 15) and adenoma (n=21)
patients, and from normal mucosa of
controls (n=8). There were no differences
in FA profile of both plasma phospho-
lipids and normal mucosa, between ade-
noma and control patients. There were
considerable differences, however, in FAs
between diseased and paired normal
mucosa of adenoma patients, with
increases of linoleic (p=0.02), dihomo-
gammalinolenic (p=0.014), and eico-
sapentaenoic (p=0.012) acids, and
decreases of a linolenic (p=0.001) and
arachidonic (p=0.02) acids in diseased
mucosa. A stepwise reduction of eico-
sapentaenoic acid concentrations in
diseased mucosa from benign adenoma to
the most advanced colon cancer was seen
(p=0.009). Cancer patients showed lower
a linolenate (p=0.002) and higher
dihomogammalinolenate (p=0.003) in
diseased than in paired normal mucosa.
In conclusion changes in tissue n3 and n6
FA status might participate in the early
phases of the human colorectal carcino-
genesis.
(Gut 1996; 38: 254-259)
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Several epidemiological studies have suggested
that populations that consume high fat diets
have an increased risk of colon cancer.1 The
intake of saturated fat seems to account for this
association, whereas an association to poly-
unsaturated fat intake (linoleate) has not been
seen.2 The low colon cancer rate in Alaskan
Eskimos, however, has been related to the high
consumption of fish products rich in n3
polyunsaturated fatty acids (n3-PUFAs),3 sug-
gesting that fish oil may be a protective factor
in colon carcinogenesis.
On the other hand, experimental studies
support the idea that dietary n6-PUFAs can
promote carcinogenesis. Several animal studies
have shown that diets containing high propor-
tions of n6-PUFAs increase the incidence of
chemically induced colonic tumours in rats,4A6
whereas diets rich in n3-PUFAs tend to have
an antipromotional effect.4 6-8 Fish oil seems
to influence early stages of colon experimental
carcinogenesis, with a decrease in proliferative
indices and focal areas of dysplasia in
azoxymethane treated rats.9 These studies
support that the fatty acid composition of the
diet is more important than its overall fat
content in terms of colon cancer risk. Recent
data also suggest a role for PUFAs on human
colon carcinogenesis. Firstly, studies on the
mucosal fatty acid content in patients with
colorectal carcinoma have shown increased
concentrations of both arachidonic (C20:4n6)
and docosahexaenoic (DHA; C22:6n3) acids
in tumoral mucosa.10 1 Nevertheless, these
abnormalities could be a metabolic con-
sequence of the established cancer rather than
a causative factor for colon carcinogenesis.
Secondly, n3-PUFA supplementation in
healthy subjects,12 and in patients with
sporadic adenomatous polyps'3 14 reduces the
rate of colonic epithelial cell proliferation, thus
decreasing the risk for colon cancer.15
In this study, a different approach to assess
the possible role of PUFAs in the colorectal
carcinogenesis processes was used. We investi-
gated the changes of the mucosal fatty acid
content in the human adenoma-carcinoma
sequence, using biopsy specimens from
patients with adenomas and carcinomas of the
colon. Measurements were performed in both
diseased and adjacent normal mucosa. The
study of colorectal adenomas avoids the
possible influence on PUFA metabolism of an
established cancer. Fatty acid profile in plasma
phospholipids was also evaluated.
Methods
Inclusion criteria
Patients who were found to have either
sporadic polyps (with size > 1 cm) or cancer of
the colon during total fibreoptic colonoscopy
were selected if they were not taking drugs
(such as hypolipemiant, oral contracep-
tives, non-steroidal anti-inflammatory drugs
(NSAIDs) or platelet antiaggregants) or
vitamin, mineral or fish oil supplements.
Likewise, only omnivore subjects taking a
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patients with associated acute or chronic
diseases that could disturb plasma fatty acid
pattern, or history of previous colorectal ade-
nomatous polyps or carcinoma were excluded.
The same inclusion criteria were required for
patients with normal colon.
All patients gave informed consent to the
study, which was approved by the Hospital
Research and Ethical Committee.
Patients
Forty nine patients with colonic adenoma or
adenocarcinoma were studied. Twenty seven
patients (22 men, five women; mean (SEM)
age 61.9 (2) years) had sporadic adenomatous
polyps (mean (SEM) size, 2.01 (0 20) cm).
Most of them were tubular adenomas (n= 12)
and tubulovillous adenomas (n= 14), and only
one was a villous adenoma. Eight adenomas
had severe cellular atypia considered as in situ
carcinoma. The sites of the polyps were rectum
(n=9), sigmoid (n=11), descending (n=6),
and ascending colon (n= 1).
Twenty two patients (16 men, six women;
mean (SEM) age 61 (2.7) years) had colorectal
adenocarcinomas. Cancer staging according to
Dukes's was: Dukes's B, 12; and Dukes's
C-D, 10. The location of the cancers were
rectum (n= 10), sigmoid colon (n=6), and
caecum plus ascending colon (n= 6).
In addition, 12 patients (six men, six
women; mean (SEM) age 57 (3.6) years) with
normal colon during a routine total fibreoptic
colonoscopy to rule out colonic disease (haem-
orrhoidal bleeding, abdominal pain, irritable
bowel syndrome) were also studied, and con-
stituted the control group. There were no
significant differences in sex and age between
the three clinical groups.
Biopsy specimens and blood collection
Biopsy specimens were taken with endoscopic
forceps. In patients with polyps or carcinoma,
specimens were taken as paired samples, from
the tumour and from normal looking mucosa
at least 10 cm away from the lesion. If
more than one polyp larger than 1 cm was
found, only the largest one was studied. In
patients with normal colon, biopsy specimens
were taken from the rectosigmoid colon.
Immediately after removal, the biopsy speci-
mens were placed in cryovials, flash frozen in
liquid nitrogen, and stored at -80°C. Polyps
were removed by snare diathermy and retained
for histological examination. Multiple biopsy
TABLE I Nutritional status of the patients studied. Values are mean (SEM)
Controls (n=12) Polyps (n=27) Cancer (n=22) p Value
TSF (%) 92-3 (7.3) 90-3 (6-1) 76-3 (10-2) NS
MAMC (%) 112 (30) 111-3 (26) 107-1 (48) NS
BMI (kg/M2) 27-5 (1-18) 26-9 (0.69) 25-7 (1-08) NS
Serum albumin (g/l) 46 (0.60) 45-7 (0.83) 39-2 (1-04)* 0-001
Prealbumin (mg/dl) 28-1 (1.1) 27-5 (1-3) 22-1 (1-76)* 0-02
RBP (ng/dl) 4-2 (0-15) 4-12 (0.22) 2-98 (03 1)* 0.004
Vitamin A (ratio) 1-07 (0.08) 1-04 (0.04) 1-15 (0-15) NS
Vitamin E (ratio) 1068 (48.2) 1074-2 (41-5) 1075-4 (57.3) NS
Vitamin C (mg/l) 7-5 (1-03) 8-5 (0.73) 5.9 (0.98) NS
*Cancer v control and polyp groups. TSF=triceps skinfold thickness, MAMC=mid-arm muscle
circumference, RBP=retinol binding protein.
specimens were obtained from suspected carci-
noma lesions for histological examination.
Venous blood was obtained the day after
colonoscopy, before any therapeutic procedure
was performed, after a 12 hour overnight fast
period. Plasma was separated by centrifugation
at 3000Xg for 10 minutes and was immedi-
ately stored at -20°C.
Fatty acid assay
The plasma lipid extraction procedure
has been previously described.'6 Plasma
phospholipids were separated by thin layer
chromatography on silica gel G-60 (Merck,
Darmstadt, Germany) by using the solvent
system described by Skipski and Barclay.'7
Direct transesterification of fatty acids (FAs)
was immediately carried out in methanol-ben-
zene 4:1 (v/v) with acetyl chloride according to
the procedure of Lepage and Roy.'8 The
benzene extract was evaporated under a stream
of nitrogen at 40°C to complete dryness. The
residue was dissolved in 100 ,u of benzene and
a 1 pAl aliquot was injected in the chromato-
graph. FA methyl esters were quantified by
gas-liquid chromatography in a Perkin-Elmer
Autosystem chromatograph (Perkin-Elmer,
Norwalk, CT) using a 30 m capillary column,
0.25 mm internal diameter, impregnated with
SP-2330 as stationary phase. The identifica-
tion and quantification of FA methyl esters
were made by comparison with an external
standard (Sigma Chemical, St Louis, MO).
FAs from C16:0 to C24:0 were measured,
unidentified peaks accounting for <05°/o of
the total FA. Saturated fatty acids (SFAs) were
expressed as the sum of C 16:0 (palmitic),
C18:0 (stearic), and C24:0 (lignoceric); and
monounsaturated fatty acids (MUFAs) as the
sum of C16:1n7 (palmitoleic), C18:1n9
(oleic), C20:1n9 (gadoleic), C22:1n9 (erucic),
and C24: 1n9 (nervonic). FAs in plasma phos-
pholipids were expressed as a percentage of the
total FAs present.
Tissue samples (mean wet weight, 27 mg;
range, 10 to 40 mg), were put in a 4:1 (v/v)
methanol-benzene solution and shaken for
about one minute in a vortex mixer.
Afterwards they were homogenised by sonica-
tion in an ultrasound bath. Then, direct trans-
esterification was performed as described
above. The procedure for FA assay did not
differ from that described for FA plasma phos-
pholipids. Mucosal FAs were expressed as per-
centage of total FAs present.
In addition, the unsaturation index (UI) was
calculated as previously described'9 according
to this equation:
UI=(FA per cent valueXnumber of double bonds)
Nutritional status
Protein-energy nutritional status was evaluated
measuring the following nutritional parame-
ters: triceps skinfold thickness, mid-arm mus-
cle circumference, body mass index (BMI),
serum albumin, prealbumin, and retinol bind-
ing protein. Triceps skinfold thickness and
mid-arm muscle circumference values were
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TABLE II Per cent distribution ofFAs in plasma phospholipids. Values are mean (SEM)
Controls (n=12) Polyps (n=27) Cancer (n=22) p Value
SFAs 44-9 (0.45) 45.7 (0.52) 47-3 (0.35)* 0.003
MUFAs 15.9 (0.53) 16.5 (0.47) 16.9 (0.53) NS
n3-PUFA
C18:3n3 0-11 (0-01) 0-12 (0-01) 0 10 (0 01) NS
C20:5n3 0.70 (0.07) 0.73 (0.06) 0-46 (0.03)* 0-0001
C22:5n3 0.47 (0.05) 0-66 (0.05) 0-58 (0.06) NS
C22:6n3 3-45 (0.15) 3.71 (0.21) 3-42 (0.19) NS
n6-PUFA
C18:2n6 18.95 (0.91) 17-35 (0.52) 16.6 (0.42)t 0.05
C18:3n6 0-19 (0.02) 0-15 (001) 0-17 (0.02) NS
C20:2n6 0-42 (0.02) 0.49 (0.06) 0 43 (0.02) NS
C20:3n6 2-84 (0-18) 2-89 (0-17) 2-90 (0-14) NS
C20:4n6 10-2 (0.32) 9-95 (0.49) 9-38 (0.37) NS
C22:4n6 1-69 (0.09) 1-58 (0.07) 1-45 (0.06) NS
C22:5n6 0-14 (0-01) 0.17 (0-01) 0-20 (0-01) NS
UI 138.9 (1-3) 137-8 (2.5) 130-7 (2.2)t 0.01
*Cancer v control and adenoma groups, tcancer v control group.
expressed as per cent of the median value of
the reference population living in our area.20
In addition, plasma vitamins A, E, and C
concentrations were measured. The aliquot for
vitamin C assay was mixed with 5% metaphos-
phoric acid at a 1:9 v/v ratio before freezing.
Vitamins A and E were measured by high per-
formance liquid chromatography and vitamin
C by fluorescence spectrophotometry as
described.2' 22 Vitamin A was expressed as
vitamin A:retinol binding protein molar ratio,
and vitamin E as vitamin E: (choles-
terol +triglycerides) molar ratio.
Statistical methods
Statistical analysis was performed using the
Biomedical Data Processing statistical pack-
age, BMDP-PC90 (BMDP, Statistical Soft-
ware, Los Angeles, CA, 1990).23
Results were expressed as mean (SEM).
For unpaired data, one way analysis of vari-
ance was used to assess differences between
means. Levene's test was used to assess the
equality of group variability. If variances were
not assumed to be equal, the Brown-Forsythe
test was used. Post-hoc pairwise comparisons
were performed by the Tukey test to identify
which group differences account for the
significant overall F value. In this multiple
comparison test the significance level is
adjusted for the number of comparisons
made.
Paired t test or the non-parametric Wilcoxon
signed rank test were used to compare mucosal
FAs values of adenomas and carcinomas with
the values in adjacent normal mucosa.
As FA status cannot be measured by a single
TABLE iII FAs (%) in normal mucosa from control, adenoma, and cancer patients.
Values are mean (SEM)
Controls (n=8) Polyps (n= 21) Cancer (n=15) p Value
SFAs 33 (1.11) 35-7 (0.69) 34.5 (0.54) NS
MUFAs 34.6 (2 22) 31-4 (1-12) 33-8 (1-24) NS
n3-PUFA
C18:3n3 0.23 (0.02) 0 24 (0-04) 0-19 (0.02) NS
C20:5n3 0.76 (0.18) 0-63 (0.08) 0 43 (0.07) 0.09
C22:6n3 2-71 (0.33) 2.90 (0-18) 2-41 (0o16) NS
n6-PUFA
C18:2n6 14 6 (0.80) 13-8 (0.47) 15-1 (0.84) NS
C18:3n6 0-19 (0.04) 0-21 (0.03) 0-20 (0.05) NS
C20:3n6 1-61 (0-14) 1-78 (0.08) 1-73 (0-14) NS
C20:4n6 11-4 (0.88) 12-3 (0.55) 10-9 (0.57) NS
C22:4n6 0-83 (0.08) 0.94 (0.05) 0.77 (0.05) NS
UI 138-8 (0.08) 139-4 (2.7) 133-5 (2.2) NS
variable, many variables must be considered
together. This necessitates a large number of
statistical comparisons, but it is the only satis-
factory way of comparing FA data.
Significance was defined at p<0 05.
Marginal p values (<0 10) are also described.
Results
Nutritional status
There were no significant differences in
anthropometric parameters, BMI, serum pro-
teins, and plasma vitamins between control
and adenoma patients. Cancer patients, how-
ever, had significantly low values of serum
albumin, prealbumin, and retinol binding
protein compared with both control and
adenoma groups (Table 1).
Fatty acid concentrations in plasma phospholipids
Table II describes FA concentrations in
plasma phospholipids. There were no differ-
ences between control and adenoma groups.
Cancer patients had significantly increased
values of SFAs compared with both control
and adenoma groups. In addition, both eico-
sapentaenoic (EPA, C20:5n3) and linoleic
(C 1 8:2n6) acid concentrations and the UI
were significantly lower in the cancer group.
Mucosalfatty acids
Analysis of FAs could not be performed in
20% of the specimens because of technical
reasons. As a consequence, about 30% of the
paired comparisons could not be made. Thus,
only 21 adenoma, 15 cancer, and eight control
patients were included in this analysis. There
were no significant differences in the clinical
characteristics and FA values in plasma phos-
pholipids between this subgroup and the whole
group of patients.
Analysis of the normal looking mucosas
obtained from patients with colorectal polyps
and cancer showed no significant differences in
the FA pattern compared with patients with
normal colons. A trend was seen, however, to
1.2
- Plasma




Control Benign In situ Dukes's B Dukes's C-D
group adenoma carcinoma cancer cancer
adenoma
Figure 1: Changes of eicosapentaenoic acid (EPA;
C20:5n3) content in plasma phospholipids, diseased
mucosa, and adjacent normal mucosa of adenoma and
carcinoma patients. Patients with normal colon constituted
the control group. *p= 0 04 v associated normal mucosa,
tp<005 v plasma of both control group and benign
adenoma, tp= 0 009 v diseased mucosa of benign
adenoma.
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Control Benign In situ Dukes's B Dukes's C-D
group adenoma carcinoma cancer cancer
adenoma
Figure 2: Ratio of arachidonic acid:eicosapentaenoic acid
(EPA) in both diseased mucosa and adjacent normal
mucosa ofadenoma and carcinoma patients. Patients with
normal colon constituted the control group. *p= 0 01 v
associated normal mucosa; tp= 0 05 v control group; and
tp= 0 03 v diseased mucosa of benign adenoma.
low EPA values in the cancer group (Table III,
Fig 1), and the arachidonate:EPA ratio was
significantly increased in cancer patients
(Fig 2).
As described in Table IV, there were notice-
able changes in mucosal FA status of both ade-
nomas and colorectal cancer compared with
their associated normal mucosa. In both
groups, there was an increase in SFAs and a
decrease in MUFAs (mainly caused by low
values of oleic acid) in the diseased mucosa.
n3-PUFA pattern in diseased mucosa was
significantly different from that in paired
normal mucosa in adenoma patients, with an
increase of both EPA and DHA, and a
decrease of ox linolenic acid (C18:3n3). In
cancer patients, only low values of a linolenic
acid were seen. On the other hand, the
diseased mucosa from colorectal cancer had
significantly lower values of both EPA and
DHA than diseased mucosa from adenomas.
Mucosal n6-PUFA pattern was also differ-
ent in both adenomas and colorectal cancer
compared with their associated normal mucosa
(Table IV). In polyps, there was a significant
increase in linoleic and dihomogammali-
nolenic (DGLA, C20:3n6) acids, and a
decrease in arachidonic acid values in the dis-
eased mucosa. On the other hand, cancer
patients had higher concentrations of DGLA
and adrenic acid (C22:4n6) in carcinoma
mucosa than in the associated normal mucosa.
The comparison of the FA pattern in the
diseased mucosas of benign adenoma, ade-
noma with in situ carcinoma, Dukes's B and
Dukes's C-D colorectal cancer disclosed
significant differences in the concentrations of
EPA, with a stepwise reduction of this FA from
benign adenoma to the more advanced colon
cancer (Table V, Fig 1). In addition, the
arachidonate:EPA ratio was significantly
higher in diseased mucosa from cancer patients
(mainly in Dukes's B cancer) than in diseased
mucosa from benign adenoma patients (Fig 2).
A trend to low concentrations of DHA in
Dukes's B and C-D cancer patients were also
seen. On the other hand, the UI was signifi-
cantly lower in Dukes's C-D cancer patients.
Discussion
This study shows for the first time that
mucosal n3 and n6 FA status is considerably
changed early in the colorectal adenoma-dys-
plasia-carcinoma sequence. Despite the fact
that the assessment of the mucosal FA pattern
could only be made in 70% of the patients, the
number of cases was large enough to perform
reliable statistical paired comparisons. More-
over, the subgroup of patients in whom this
analysis was performed were representative of
the whole series of patients, in terms of clinical
features and plasma FA profile. On the other
hand, interpretation of the results must be
cautious as multiple statistical comparisons
have been performed, a fact inherent to the
studies on fatty acid status, and some of the
observed significances might have arisen by
chance. In this sense, only highly significant
results and those with biological plausibility are
discussed.
As the FA pattern in both plasma phospho-
lipids and normal mucosa was not different
between patients with either adenomatous
polyps or normal colon, the observed changes
in the FA status of the diseased mucosa from
adenomas do not seem a consequence of dif-
ferences in either fat intake or hepatic FA
biosynthesis. Thus, changes of tissue lipid
biochemistry might participate in the colon
carcinogenesis processes. The observed
changes, however, are not always readily inter-
pretable on the basis of the present knowledge
on mucosal FA metabolism. Tissue FA pattern
may be the result of a combination of different
phenomena including liver biosynthetic
TABLE IV FAs (%o) in paired normal and diseased mucosa from colonic adenomas and colorectal carcinomas. Values are
mean (SEM)
Colon adenoma (n=21) Colon cancer (n 15)
Normal mucosa Diseased mucosa p Value Normal mucosa Diseased mucosa p Value
SFAs 35-7 (0.7) 37-3 (0.8) 0.001 34-5 (0.5) 38-0 (0.97) 0-0002
MUFAs 31-4 (1-12) 29-0 (0.8) 0-07 33-8 (1-2) 30-8 (1-06) 0 053
n3-PUFAs
C 18:3n3 0-24 (0-03) 0-14 (0.01) 0 001 0.19 (0.02) 0-13 (0.02) 0-002
C20:5n3 0-63 (0.07) 0-80 (0.09) 0-012 0-43 (0.07) 0-40 (0.07)t NS
C22:6n3 2-90 (0-18) 3-22 (0.19) 0-06 2-40 (0-16) 2-61 (0.18)t NS
n6-PUFAs
C18:2n6 13-8 (0.5) 14-9 (0.4) 0-02 15-1 (0.84) 13-8 (0.66) NS
C18:3n6 0-21 (0.03) 0-23 (0.05) NS 0-20 (0.05) 0.19 (0.04) NS
C20:3n6 1-78 (0.08) 2-26 (0-18) 0-014 1-73 (0-14) 2-20 (0.24) 0.003
C20:4n6 12-3 (0.55) 11-2 (0.37) 0-02 10.9 (0.56) 10-7 (0.49) NS
C22:4n6 0.94 (0.05) 0.94 (0.05) NS 0-76 (0.05) 1-06 (0-14) 0-03
UI 139-4 (2.7) 138-6 (2.6) NS 133-5 (2.2) 130-8 (2.6)* NS
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TABLE V FAs (%o) in diseased mucosa from patients with colon adenoma and colon
cancer. Comparison of benign colon adenoma, adenoma with in situ carcinoma, Dukes's B,
and Dukes's C-D colorectal cancer. Values are mean (SEM)
Benign In situ carcinoma Dukes's Dukes's
adenoma adenoma B cancer C-D cancer p
(n=15) (n=6) (n=8) (n=7) Value
SFAs 37-8 (1.0) 35-8 (0.9) 37-1 (1-3) 39-0 (1-39) NS
MUFAs 29-4 (0.97) 28-1 (1-55) 30-8 (1-72) 30-9 (1-31) NS
n3-PUFAs
C18:3n3 0-15 (0.02) 0.09 (0.02) 0-15 (0.04) 0.12 (0.02) NS
C20:5n3 0-88 (0.11) 0-61 (0-14) 0-42 (0-12) 0-38 (0.03)* 0.009
C22:6n3 3.09 (0 22) 3-55 (0.36) 2-48 (0.19) 2-75 (0.32) 0.10
n6-PUFAs
C18:2n6 14-4 (0.4) 16-1 (0-9) 14-2 (1-05) 13-4 (2 82) NS
C18:3n6 0-26 (0.07) 0-18 (0.05) 0-22 (0.07) 0-15 (0.05) NS
C20:3n6 2-30 (0.25) 2-17 (0-15) 2-55 (0.42) 1-81 (0-15) NS
C20:4n6 10-6 (0.45) 12-4 (0.40) 10.9 (0.69) 10-4 (0.73) NS
C22:4n6 0.94 (0.05) 0.95 (0-13) 1.10 (0.25) 1.01 (0.10) NS
UI 135-8 (3.4) 145-3 (1-7) 133-1 (3.4) 128-2 (3.9) 0.05
*Dukes's C-D v benign adenoma, tDukes's C-D v adenoma with in situ carcinoma.
activities, selective plasma FA uptake, esterifi-
cation reactions, own synthetic activity, molec-
ular selection of FAs in association with
specific membrane proteins, and increased
utilisation of particular FAs.24 Whatever the
mechanism, the findings of this study may be
of relevance in the understanding of the role of
lipids in colorectal carcinogenesis.
One of the most striking findings in this
study is the appreciable change in mucosal
EPA concentrations. There was a stepwise
reduction of mucosal EPA values from benign
adenoma to the most advanced colon cancer,
mainly in the diseased mucosa, whereas
plasma concentrations were only decreased in
cancer patients. In addition, EPA content in
adenoma tissue was increased compared with
adjacent normal mucosa. These results rein-
force the suggestion that long chain n3-PUFA
(fish oil) may influence early stages of colon
carcinogenesis.9 13 14 Recent work in humans
shows that low dose fish oil supplementation
(2.5 g/day for one month) normalises the rectal
mucosal cell proliferation pattern in patients
with sporadic colonic adenomas. 14 In that
study, doubling the rectal mucosal EPA
content after supplementation was enough to
significantly decrease the epithelial prolifera-
tive indices. However, whether the stepwise
reduction of tissue EPA values in the ade-
noma-dysplasia-carcinoma sequence, as seen
in this study, is related to increased rectal cyto-
kinetics has to be evaluated.
Mucosal arachidonate values, expressed as
,ug/g of tissue, were reported to be significantly
higher in colorectal cancer than in normal adja-
cent mucosa.10 In two other studies, however,
there were no significant differences when
expressed as a proportion of total FAs." 25 In
this study, values of this FA, also expressed as a
proportion of total FAs, were not increased, but
the mucosal arachidonate:EPA ratio was signifi-
cantly higher in colon cancer compared with
adenoma and control patients. Several studies
have suggested that effects of PUFAs in tumour
development and progression may be mediated
by modulation of prostaglandin synthesis and
metabolism.7 1012 26 Arachidonic acid gives rise
to the 2-series prostaglandin, EPA generates the
3-series prostaglandin, andDGLA produces the
1-series prostaglandin. Competitive effects
occur between these precursor FAs in the
cyclooxygenase reaction. Therefore, a high
arachidonate:EPA ratio implies more substrate
for prostaglandin E2 synthesis. In fact, increased
local production of prostaglandin E2 has been
reported in human colon cancer and colonic
adenomas compared with paired normal
mucosa.102527 In addition, it has been postu-
lated that the inhibitory effect of n3-PUFA
upon experimental colon cancer and human
rectal epithelial proliferation may result from
the suppression of excessive production of
prostaglandin E2.7 12-14 On the other hand, con-
centrations of DGLA were increased in both
adenoma and cancer diseased mucosas com-
pared with paired normal tissue. Thus,
1-series prostaglandin might also participate in
colorectal carcinogenesis.
It has been recently shown that the
cyclooxygenase 2 gene expression is consider-
ably increased in most human colorectal
cancers and in a subset of adenomas compared
with the adjacent normal mucosa.28 Therefore,
changes in the tissue FA pattern of our patients
would also be caused by differences in FA
utilisation to generate eicosanoids.
Tissue PUFAs may also exert growth regu-
lating functions by the inositol lipid cycle,24
through the activation of protein kinase C.29
Enrichment of cell membranes with n3 or n6-
PUFAs have opposite effects on this signalling
pathway in a human colon cancer cell line,30
and it has been shown that arachidonate may
stimulate cell proliferation by activating pro-
tein kinase C and other kinases.31 32 Recent
data suggest that changes in the inositol lipid
cycle may occur early in the adenoma-carci-
noma sequence.33 On the other hand, it has
been shown that n3 and n6-PUFAs may have
opposite regulatory effects on the activity and
expression of the gene product of cellular ras
proto-oncogenes.34 35
An important physical property of cell
membranes is their fluidity, one of the major
factors regulating it being the unsaturation in
the FAs chains.24 Therefore, the finding of a
decrease in the UI only in the patients with
advanced colon cancer, suggests that cell
membrane fluidity is reduced late in colon
carcinogenesis. An increase of SFAs and a
decrease of MUFAs tissue values seem to
account for the low UI seen. Changes in
fluidity may affect the efficiency of diverse
metabolic processes that occur in the mem-
brane matrix. Therefore, the role of mem-
brane fluidity in tumour progression and
dissemination should be studied.
In summary, although many questions
remain, results of this study suggest that
changes in tissue PUFA biochemistry may par-
ticipate in the human colorectal carcino-
genesis. Further investigation is necessary to
determine the putative role of these changes
and whether or not longterm dietary manipula-
tion may modify human tumour growth and
progression.
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